Glucagon-Like Peptide-1 Receptor Agonists Reduce Surgeries and Hospitalizations in Hidradenitis Suppurativa: A Multicenter TriNetX Cohort Study

Le résumé fourni par la source

BACKGROUND: Hidradenitis suppurativa is a chronic inflammatory skin condition frequently associated with type 2 diabetes mellitus and obesity. Glucagon-like peptide-1 receptor agonists have emerged as promising agents for managing type 2 diabetes mellitus due to their potent effects on glycemic control and weight reduction. Recent evidence suggests that glucagon-like peptide-1 receptor agonists may also possess anti-inflammatory properties, potentially making them effective in treating inflammatory conditions, such as hidradenitis suppurativa. OBJECTIVE: To determine if glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in patients with hidradenitis suppurativa. METHODS: We utilized the TriNetX platform to evaluate the rate of surgical abscess repairs performed and hospitalizations in a propensity score-matched cohort of patients with hidradenitis suppurativa who were prescribed glucagon-like peptide-1 receptor agonists. RESULTS: Our analysis revealed that patients prescribed glucagon-like peptide-1 receptor agonists had significantly lower rates of surgeries with a HR of 0.35 (95% CI: 0.25, 0.50) and hospitalizations with a HR of 0.87 (95% CI: 0.82, 0.92) compared to a control cohort of patients who did not receive glucagon-like peptide-1 receptor agonists. CONCLUSIONS: Glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in hidradenitis suppurativa, demonstrating their potential therapeutic value in dermatology patient care.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.